EphB4 Antibody ( FITC )

EphB4 Antibody Datasheet

EphB4 Antibody Product Information

• Immunogen: Recombinant Human EphB4 protein (Catalog#10235-H08H)
• Reagents: FITC-conjugated rabbit monoclonal antibody
• Clone ID: 001
• Ig Type: Rabbit IgG
• Concentration: 10 μl/Test, 0.1 mg/ml
• Formulation: Aqueous solution containing 0.5% BSA and 0.09% sodium azide
• Preparation: This antibody was obtained from a rabbit immunized with purified, recombinant Human EphB4 (rh EphB4; Catalog#10235-H08H; NP_004435.3; Met 1-Ala 539) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.

EphB4 Antibody Usage Guide

• Specificity: Human EphB4
• Flow Cytometry:
  

  Flow cytometric analysis of anti-human EphB4 on MCF-7 cells. MCF-7 cells were detached using 1X trypsin, washed, then stained with FITC Rabbit anti-human EphB4.

  Flow cytometry was performed on a BD FACSCalibur flow cytometry system

  Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.

• Storage: This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
  Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

EphB4 Antibody Background

EphB4, also known as Htk, Myk-1, is a member of the Eph subfamily of receptor tyrosine kinases (RTKs). The Ephs are divided into two classes based on their extracellular structure and ligand specificity, and the transmembrane receptor binding preferentially to ephrin-B ligands is referred to as EphB. Sharing common structure organization, all Eph receptors contain an N-terminal Ig-like domain, a cysteine-rich region and two fibronectin type III domains within the ECD, as well as the typical cytoplasmic tyrosine kinase domain. EphB4 and its ligand ephrin-B2 are specifically expressed on venous and arterial endothelial cells, respectively, and play an essential role in vascular development via bidirectional signals. The forward EphB4 signaling inhibits cell adhesion, chemotaxis, angiogenesis, and tumor growth. In contrast, the reverse Ephrin-B2 signaling exerts the opposite effect. It has been reported that aberrant expression of EphB4 is associated with prostate cancer and highly malignant breast cancers, and accordingly, EphB4 has potential applications as a therapeutic candidate.

References

1. Bennett, B.D. et al., 1994, J. Biol. Chem. 269: 14211-14218.
2. Noren, N.K. et al., 2004, Proc. Natl. Acad. Sci. 101: 5583-5588.
3. Murai, K.K. et al., 2003, J. Cell. Sci. 116: 2823-2832.
4. Noren, N.K. et al., 2006, Nat. Cell. Biol. 8: 815-825.
5. Xia, G. et al., 2005, Cancer Res. 65: 4623-4632.
6. Kertesz, N. et al., 2006, Blood. 107: 2330-2338.